Bisphenol A at Low Nanomolar Doses Confers Chemoresistance in Estrogen Receptor-α–Positive and –Negative Breast Cancer Cells | Zendy

Elizabeth W. LaPensee | Zendy; Traci R. Tuttle | Zendy; Sejal R. Fox | Zendy; Nira BenJonathan | Zendy

Open Access

Bisphenol A at Low Nanomolar Doses Confers Chemoresistance in Estrogen Receptor-α–Positive and –Negative Breast Cancer Cells

Author(s) -

Elizabeth W. LaPensee,

Traci R. Tuttle,

Sejal R. Fox,

Nira BenJonathan

Publication year - 2008

Publication title -

environmental health perspectives

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.257

H-Index - 282

eISSN - 1552-9924

pISSN - 0091-6765

DOI - 10.1289/ehp.11788

Subject(s) - estrogen receptor , gper , estrogen receptor alpha , breast cancer , cytotoxicity , fulvestrant , cancer research , pharmacology , cisplatin , estrogen , cancer , doxorubicin , cancer cell , antiestrogen , biology , chemistry , medicine , endocrinology , chemotherapy , biochemistry , in vitro

Resistance to chemotherapy is a major problem facing breast cancer patients, and identifying potential contributors to chemoresistance is a critical area of research. Bisphenol A (BPA) has long been suspected to promote carcinogenesis, but the high doses of BPA used in many studies generated conflicting results. In addition, the mechanism by which BPA exerts its biological actions is unclear. Although estrogen has been shown to antagonize anticancer drugs, the role of BPA in chemoresistance has not been examined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research